Expect Equity LLC Buys New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Expect Equity LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 24,924 shares of the medical equipment provider's stock, valued at approximately $2,230,000. Lantheus accounts for 2.3% of Expect Equity LLC's holdings, making the stock its 21st biggest position.

Other hedge funds also recently modified their holdings of the company. State of New Jersey Common Pension Fund D raised its stake in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after purchasing an additional 115 shares during the period. Bleakley Financial Group LLC boosted its holdings in Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares during the period. Avantax Advisory Services Inc. grew its position in Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after buying an additional 132 shares in the last quarter. Foundry Partners LLC increased its position in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. raised its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Truist Financial lowered their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $132.67.

Lantheus Trading Down 2.7%

NASDAQ LNTH traded down $2.22 during trading on Monday, hitting $79.52. The company had a trading volume of 2,167,057 shares, compared to its average volume of 973,734. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The company has a market cap of $5.45 billion, a price-to-earnings ratio of 13.23 and a beta of 0.23. The company's fifty day moving average is $99.15 and its 200-day moving average is $93.92.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.69 earnings per share. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.